MPS North America LLC (MPS NA LLC), a wholly owned material subsidiary of MPS Ltd, has acquired 100% stake in Unbound Medicine, Inc., a US-based healthcare technology and medical information company for $16.5 million (about Rs.140 crore).
Accordingly, Unbound Medicine, Inc., USA has become a wholly-owned step-down subsidiary of MPS Ltd. The entire deal was funded through internal accruals and term loan.
Noida-based MPS Ltd was established in 1970 as a subsidiary of Macmillan Ltd. Today, it is the premier learning and platform solutions provider operating at the intersection of content, technology, and artificial intelligence.
The acquisition marks MPS’s entry into the healthcare and medical information technology segment, a high-growth, knowledge-intensive vertical adjacent to its core strengths in digital publishing, learning platforms and technology-enabled content solutions.
MPS said the proposed transaction aligns with its long-term strategy of building platform-led, recurring-revenue businesses. The acquisition is expected to complement MPS’ existing capabilities in digital content, platform engineering and technology-enabled knowledge services, while supporting long-term value creation through revenue diversification, cross-selling opportunities and AI-driven innovation.
Founded in 1999, Unbound Medicine is a well-established provider of digital medical reference, clinical decision-support and healthcare learning solutions. The company operates proprietary mobile-first and web-based platforms that deliver evidence-based medical content to healthcare professionals, academic institutions and professional associations through a subscription-led institutional business model.
Unbound Medicine has a strong footprint across the US and Canada, serving leading medical schools, hospital systems and healthcare associations.
The deal is also expected to deepen MPS’ presence in North America, a key strategic geography for the company.
Unbound Medicine CEO Bill Detmer said: “MPS’ deep technological resources and international reach will allow us to deliver our AI-driven clinical tools to a wider network of learners and practitioners than ever before.”
MPS Ltd CEO Rahul Arora described the acquisition as a “transformative milestone”, marking a bold expansion into a resilient, recurring-revenue sector. The deal would unlock revenue synergies, deepen institutional relationships and accelerate innovation through MPS Labs, positioning MPS as a technology-first partner to the global healthcare community.